Reports Q2 revenue $766.5M, consensus $726.18M. Eric Green, president, CEO and chair of the board, commented: “I am pleased to report that we exceeded our expectations for the second quarter driven by solid growth in HVP components. This was the result of strong GLP-1 elastomer growth, ongoing momentum in HVP conversion mainly related to Annex 1 projects and the continued normalization of customer ordering patterns. The improved performance was concentrated in higher margin products, which drove strong margin expansion in the quarter. As a result of our strong second quarter performance and favorable foreign exchange, we are increasing our revenue and adjusted-diluted EPS guidance for fiscal year 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Services, Inc. (WST) Q2 Earnings Cheat Sheet
- West Pharmaceutical Appoints New CFO Robert McMahon
- Strategic Leadership Change at West Pharmaceutical Services Boosts Buy Rating
- West Pharmaceutical appoints Robert McMahon as CFO
- West Pharmaceutical initiated with an Equal Weight at Barclays